Industry Background:
Fractionation is a method of separating a specific amount of a mixture. Furthermore, plasma is the fluid component of blood that is separated to produce albumin and immunoglobulins, among other plasma derivatives. These plasma-derived compounds have therapeutic properties and are used to treat a variety of blood plasma-related illnesses. Coagulation factor VIII, for example, is a plasma product that is used to treat and prevent hemophilia. Additionally, it is used to prevent excessive blood loss during surgical procedures. Immunoglobulins are also used to treat immunological deficits, both primary and secondary. Immunoglobulins produced from plasma are increasingly being employed in a variety of clinical settings, including autoimmune and inflammatory illnesses. Ceruloplasmin, IgA, and Plasmin are among the medicines that the plasma fractionation market has heavily invested in. Furthermore, the market would be boosted by rising investments in innovation and technological breakthroughs in efficient and cost-effective protein fractionation techniques.This growth is primarily driven by The growing use of Immunoglobulins in Various Therapeutic Areas
.
Attributes | Details |
---|
Study Period | 2018-2028 |
Base Year | 2022 |
Forecast Period | 2023-2028 |
Volume Unit | N |
Value Unit | USD (Million) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
The Biotechnology sector in the
region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), LFB (France), Biotest (Germany), Takeda Pharmaceutical Company (Japan), Bio Products Laboratory (United Kingdom) and Bharat Serums and Vaccines Limited (India), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
In June 2021, LFB Plasma announced the acquisition of ImmunoTek Bio Center. The acquisition of the plasma collection center will ensure a steady and reliable supply of plasma in the U.S.
April 2020 – Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring) and Takeda Pharmaceutical Company Limited to develop a potential plasma-derived therapy for treating COVID-19. and April 2020 – Grifols (Spain) launched a 3-mL (900-IU) vial of HyperRAB (rabies immune globulin [human]) in the plasma fractionation market.The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new product launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Regulatory Insights:
In the United States, the FDA regulates blood plasma fractionators and the plasma-derived products they produce. The FDA sets standards and requirements for the collection, processing, and testing of plasma and its derivatives.
Influencing Trend:
Rising Prevalence of Bleeding Disorders
Market Growth Drivers:
The growing use of Immunoglobulins in Various Therapeutic Areas, Rising Geriatric Population and Increase in the Number of Plasma Collection Centers Across the Globe
Challenges:
Stringent Government Rules and Regulations
Restraints:
High Cost of Plasma-Derived Products and Emergence of Recombinant Alternatives
Opportunities:
Increased Risk of Pandemics and Communicable Diseases and Albumin Shows Lucrative Growth Opportunity
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Data Sources of Blood Plasma Fractionators Market Study
Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Blood Plasma Fractionators Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.
The primary interviews and data collected as per the below protocols: By Designation: C-Level, D-Level, Others
By Company Type: Tier 1, Tier 2, Tier 3
Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Blood Plasma Fractionators players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.
Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Blood Plasma Fractionators Study Sheds Light on
The Blood Plasma Fractionators Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Blood Plasma Fractionators industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Blood Plasma Fractionators industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.